A 32-year-old man from rural Maharashtra presents with a 3-month history of cough, fever, and weight loss. Sputum smear microscopy is positive for acid-fast bacilli. He is started on standard first-line anti-TB therapy (HRZE). After 2 months of treatment, repeat sputum smear microscopy remains positive. Which investigation is most appropriate to assess treatment failure and guide further management?

Explanation

## Investigation of Choice for Suspected TB Treatment Failure ### Clinical Context Persistent sputum smear positivity after 2 months of standard first-line therapy indicates treatment failure and raises concern for drug-resistant TB (MDR-TB or XDR-TB). ### Why Sputum Culture with DST is the Gold Standard **Key Point:** Sputum culture with drug susceptibility testing (DST) is the investigation of choice for confirming treatment failure and identifying resistance patterns. 1. **Confirms persistent TB**: Culture isolates viable organisms and confirms active disease (not just dead bacilli in sputum) 2. **Identifies resistance pattern**: DST determines susceptibility to first-line drugs (INH, RIF, PZA, EMB) and second-line agents 3. **Guides second-line regimen**: Results dictate whether MDR-TB or XDR-TB therapy is needed 4. **Prognostic value**: Helps predict treatment duration and outcomes **High-Yield:** Persistent sputum positivity at 2 months = treatment failure until proven otherwise. DST is mandatory before switching regimens. ### Timeline for Culture Results - Liquid media (MGIT): 2–3 weeks - Solid media (LJ): 4–8 weeks - DST results: additional 2–4 weeks **Clinical Pearl:** While awaiting DST, WHO recommends empirical switch to MDR-TB regimen (fluoroquinolone + injectable + bedaquiline-based) if clinical suspicion is high and sputum remains positive at 2 months. ### Comparison with Other Investigations | Investigation | Role | Limitation in This Case | |---|---|---| | **Sputum culture + DST** | Gold standard for resistance detection | Takes 4–12 weeks; delays therapy | | **HRCT chest** | Assesses extent of disease, complications | Does not identify drug resistance | | **Bronchoscopy + BAL** | Diagnostic when sputum smear negative | Invasive; does not add value when sputum is already positive | | **TB-LAMP antigen** | Rapid TB detection (2 hours) | Detects TB presence, not resistance; not used for treatment failure assessment | **Warning:** Do not delay second-line therapy while waiting for culture/DST results if clinical suspicion of MDR-TB is high.